Global pharmaceutical firms are committing unprecedented capital to construct contract development and manufacturing organization (CDMO) infrastructure dedicated to metabolic treatments.
Capacity Bottlenecks
Current fill-finish capacity remains severely constrained despite 24/7 facility operations. Companies are spending over $15 billion globally to acquire and upgrade sterile injectable plants.
Market Expansion
As clinical trials evaluate GLP-1 efficacy in cardiovascular and renal conditions, total addressable demand is expected to expand far beyond primary weight-management indicators.